![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Mylan Laboratories Limited Hyderabad In, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Letrozole, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2013-214 - Rev 00
This Chemical Type CEP, issued on October 01, 2019, remains in force until September 16, 2020, ensuring its reliability within the pharmaceutical industry.
Substance Number 2334 associated with this CEP further emphasizes